Ring 1
Ring 2
Ring 3
Ring 4

Carisma Therapeutics

Financing Rounds

  • Series B
  • Public
Round Led by Symbiosis
Round Led by Symbiosis

Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.

carisma View Website

Modality

  • Cell Therapy

Indications

  • Immunology
  • Neurology
  • Oncology

Development Status

  • Phase 1